EC Declaration of Conformity

according to Directive 98/79/EC, on in vitro diagnostic medical devices

Ref. No.:20220513-A05

Manufacturer (Name, Address) Getein Biotech, Inc.

No. 9 Bofu Road, Luhe District, Nanjing, 211505, China

Authorized Representative (Name, Address) CMC Medical Devices & Drugs S.L.

Add: C/ Horacio Lengo Nº 18, CP 29006, Málaga, Spain

	No.	Product Name
	1	Getein 1100 Immunofluorescence Quantitative Analyzer
2 3	/ 2	Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay)
	//3 ///	NT-proBNP Fast Test Kit (Immunofluorescence Assay)
	4 ///	hs-CRP+CRP Fast Test Kit (Immunofluorescence Assay)
	5	NT-proBNP/cTnI Fast Test Kit (Immunofluorescence Assay)
	6	CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay)
	7	D-Dimer Fast Test Kit (Immunofluorescence Assay)
	8	PCT Fast Test Kit (Immunofluorescence Assay)
	9	CysC Fast Test Kit (Immunofluorescence Assay)
	10	mAlb Fast Test Kit (Immunofluorescence Assay)
	M//	NGAL Fast Test Kit (Immunofluorescence Assay)
11/////	12	β2-MG Fast Test Kit (Immunofluorescence Assay)
Medical device	13	CK-MB/cTnI Fast Test Kit (Immunofluorescence Assay)
	14	HCG+β Fast Test Kit (Immunofluorescence Assay)
	15	H-FABP Fast Test Kit (Immunofluorescence Assay)
	16	PCT/CRP Fast Test Kit (Immunofluorescence Assay)
	17	CK-MB/cTnI/H-FABP Fast Test Kit (Immunofluorescence Assay)
	18	HbA1c Fast Test Kit (Immunofluorescence Assay)
	19	NT-proBNP/NGAL Fast Test Kit (Immunofluorescence Assay)
	20	CK-MB Fast Test Kit (Immunofluorescence Assay)
	21	hs-cTnI Fast Test Kit (Immunofluorescence Assay)
	22	T3 Fast Test Kit (Immunofluorescence Assay)
	23	T4 Fast Test Kit (Immunofluorescence Assay)
	24	TSH Fast Test Kit (Immunofluorescence Assay)
	25	Scr Fast Test Kit (Immunofluorescence Assay)
	26	PLGF Fast Test Kit (Immunofluorescence Assay)



Solution in the second				***
	67	HBP Fast Tes	t Kit (Immunofluorescence Assa	ay)
	68	S100-β Fast T	est Kit (Immunofluorescence A	ssay)
	69	CK-MB/hs-c7	InI/Myo Fast Test Kit (Immuno	fluorescence Assay)
			Test Kit (Immunofluorescence A	and the second second
			t Kit (Immunofluorescence Ass	Company of State of S
	72	AFP/CEA Fa	st Test Kit (Immunofluorescer	nce Assay)
Classification	Other device ((according to	Annex II of the directive 98	B/79/EC)
Conformity assessment route	Annex III of the	e 98/79/EC		
Applicable	EN 13612:200	02	EN ISO 14971:2019	EN ISO15223-1:2016
coordination	EN ISO 18113	3-1:2011	EN ISO 18113-2:2011	EN ISO 18113-3:2011
standards ///	EN ISO 2364		EN ISO 13485:2016	ISO 780:2015
	EN 61326-2-6		IEC 61326-1:2013 IEC 61010-1:2010	
7 111	EN 61010-2-1	101.2002	120 0 10 10-1.20 10	111 111 111
Annex III. The comp Annex III are testifie	oiled technical file d and the quality r is exclusively re	and quality system cert	ean Parliament and the Cou system document accordin tificate has issued by BSI G or the declaration of conforn	g to 98/79/EC directive roup The Netherlands B.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document accordin tificate has issued by BSI G	g to 98/79/EC directive roup The Netherlands B.
Annex III. The comp Annex III are testifie V. The manufacture	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signature)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.
Annex III. The comp Annex III are testifie V. The manufacture General Manager Nowing	oiled technical file d and the quality r is exclusively re Enben Su	and quality system cert	system document according tificate has issued by BSI Gor the declaration of conform (name and signatur marking of author)	g to 98/79/EC directive roup The Netherlands B. nity.





Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that: Getein Biotech, Inc.

No.9 Bofu Road Luhe District Nanjing Jiangsu 211505 China 基蛋生物科技股份有限公司

中国 江苏省 南京市 六合区

沿江工业开发区 博富路9号 邮编: 211505

Holds Certificate No: MD 728432

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay). Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay). 研发,生产和销售化学发光法试剂,生化试剂,即时诊断(包括胶体金法,免疫荧光法,干式化

学法)试剂。 研发,生产和销售用于化学发光法试剂,生化试剂,即时诊断(包括胶体金法,免疫荧光法, 于式化学法)试剂配套使用的分析仪。

For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

jany C Stade

Original Registration Date: 2020-05-29 Effective Date: 2020-07-26 Latest Revision Date: 2020-07-22 Expiry Date: 2023-07-25

Page: 1 of 1

bsi.



...making excellence a habit."

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract. An electronic certificate can be authenticated online.

Printed copies can be validated at www.bsi-global.com/ClientDirectory or telephone +86 10 8507 3000.



Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China Tel: 86-25-68568508 Email: overseas@geteincom.cn Web: www.bio-GP.com.cn

Document No.: GP-GMSQ-2022-110

Letter of Authorization

To whom it may concern,

We, Getein Biotech, Inc. (No.9 BoFu Road, Luhe District, Nanjing, 211505, China), hereby authorize Sanmedico SRL. as our official distributor for registering, promoting, selling, distributing, taking part in tenders, maintaining & after sale technical services of under-mentioned product in the territory of Moldova:

Sanmedico SRL will comply with the laws and regulations of the countries and regions where they are located in and where they are selling mentioned product to, otherwise, the risks and losses arising therefrom shall be undertaken by Sanmedico SRL

This authorization starts from Jan 1, 2022 and will be valid to December 31 2023

Getein Biotech, Inc. has the right to terminate the authorization before validity and will inform Sanmedico SRL with 10 days in advance.

Getein Biotech, Inc.

Name: Steven Zhou

Position: Overseas Sales Director

基蛋生物科技股份有限公司 GETEIN BIOTECH, INC.

Stron There





CK-MB/cTnl/Myo Fast Test Kit

(Immunofluorescence Assay)

User Manual

Getein1100: Cat.# IF1005 Getein1600: Cat.# IF2005

INTENDED USE

CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay) is intended for *in vitro* quantitative determination of CK-MB/cTnI/Myo in serum, plasma or whole blood. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Creatine kinases are dimer isozymes composed of two monomer subunits, CK-M (for skeletal muscle derived) and CK-B (for brain derived), which can form all three combinations of monomers: CK-BB, CK-MM, and CK-MB, BB is found primarily in the brain. Skeletal muscles primarily contain the MM isoform, with trace amount of MB (around 1-4% of total CK activity). Cardiac muscles also contain the MM isoform, but higher amount of MB, typically around 20% of total CK activity. CK-MB is a more sensitive marker of myocardial injury than total CK activity, because it has a lower basal level and a much narrower normal range. Medical literatures commonly state that CK-MB levels are elevated in 4 to 6 hours, peak at 10 to 24 hours, and return to normal within 3 to 4 days after an acute myocardial infarction. Classically, an increase of the myocardialspecific enzyme CK-MB is considered as the hallmark of acute myocardial infarction, and increased levels are frequently interpreted by the clinician as objective evidence of myocardial cell damage.

Troponin complex consists of three regulatory proteins: T, which connects the troponin complex and tropomyosin (another

cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardia.

Clinical studies have demonstrated the release of cTnl into the blood stream within hours following acute myocardial infarctions (AMI) or ischemic damage. Elevated levels of cTnl are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnl has become an important marker in the diagnosis and evaluation of patients suspected of having an AMI.

Myoglobin is a small monomeric protein which serves as an intracellular oxygen storage site. It is found in abundance in the muscle and can get through into the blood circulation directly when myocardial cell is damaged mildly. Therefore, myoglobin has been advocated as a sensitive marker for early acute myocardial injury by American College of Cardiology Committee

PRINCIPLE

Mixed monoclonal antibodies against human CK-MB, cTnl and Myo are conjugated with fluorescence latex and another set of anti-human CK-MB/cTnl/Myo monoclonal antibodies were coated on different test lines respectively. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CK-MB, cTnl and Myo monoclonal antibodies will bind with the CK-MB, cTnl and Myo in sample respectively and form marked antigen-antibody complexes. These complexes move to the test card detection zone by capillary action. Then marked antigen-antibody complexes will be captured on different test lines by another set of monoclonal antibodies against human CK-MB, cTnl or Myo respectively resulting in the accumulation of fluorescence particles on the test lines. The fluorescence intensity of each test line increases in proportion to the amount of CK-MB, cTnl or Myo in sample.

Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of CK-MB, cTnI and Myo

in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to LIS and HIS.

CONTENTS

١.	Α	kit	for	Getein1100	0 contains
----	---	-----	-----	------------	------------

Getein CK-MB/cTnI/Myo test card in a sealed pouch wi
desiccant ····· 2
Disposable pipet ····· 2
Whole blood buffer ····· 1
SD card 1
User manual ······ 1
A kit for Getein1600 contains:
Sealed cartridge with 24/48 Getein CK-MB/cTnI/Myo test card

User manual 1 Package specifications: 2×24 tests/kit, 2×48 tests/kit Materials required for Getein1600: Sample diluent 1 Box with pipette tips 1

- 4. A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with fluorescence latex-labelled anti-human CK-MB, cTnl and Myo monoclonal antibodies, these three lines are coated with another anti-human CK-MB, another anti-human cTnl and another anti-human Myo monoclonal antibody, respectively. and the control line C is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer

Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.

For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

Store the sample diluent/whole blood buffer at $0\sim30^{\circ}$ C with a valid period of 24 months.

Store the sample diluent/whole blood buffer at $2\sim8^{\circ}C$ for better results.

PRECAUTIONS

- 1. For in vitro diagnostic use only.
- For professional use only.
- Do not use the kit beyond the expiration date.
- Do not use the test card if the foil pouch or the cartridge is damaged.
- Do not open pouches or the cartridge until ready to perform the test.
- 6. Do not reuse the test card.
- 7. Do not reuse the pipet.
- Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
- Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

- This test can be used for serum, plasma and whole blood samples. Heparin and sodium citrate should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
- 2. Suggest using serum or plasma for better results.
- Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.
- 4. If testing will be delayed, serum and plasma samples may

- be stored up to 7 days at $2\sim8^{\circ}\text{C}$ or stored at -20°C for 6 months before testing (whole blood sample may be stored up to 3 days at $2\sim8^{\circ}\text{C}$).
- Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freezethaw cycles.
- 6. Do not use heat-inactivated samples.
- 7 SAMPLE VOLUME (for Getein1100): 100 µl.

TEST PROCEDURE

- 1. Collect specimens according to user manual.
- Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

- Confirm SD card lot No. in accordance with test kit lot No.. Perform "SD Card Calib" calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
- 4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
- Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification
- 6. Put the test card on a clean table, horizontally placed.
- 7. Using sample transfer pipette, deliver 100 μl of sample (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 100 μl sample on the test card).
- Reaction time: 15 minutes. Insert the test card into Getein1100
 and press "ENT" button after reaction time is elapsed. The
 result will be shown on the screen and printed automatically.

For Getein1600:

- Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
- 10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

- It is required to perform "SD Card Calib" calibration when using a new batch of kits.
- It is suggested to calibrate once for one batch of kits for Getein 1100.

Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for CK-MB was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for CK-MB is 5.0 ng/ml. (The probability that value of a normal person below 5.0 ng/ml is 99%.)

The expected normal value for cTnI was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.1 ng/mI. (The probability that value of a normal person below 0.1 ng/mI is 99%.)

The expected normal value for Myo was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for Myo is 50 ng/ml. The 97.5th percentile of the concentration for Myo is 70 ng/ml. (According to different Statistics method, the probability that value of a normal person below 50 ng/ml is 95% or below 70 ng/ml is 97.5%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

	CK-MB	cTnI	Myo
Measuring Range	2.5~80.0 ng/ml	0.1~50.0 ng/ml	30.0~600.0 ng/ml
Lower Detection Limit	≤ 2.5 ng/ml	≤ 0.1 ng/ml	≤ 30.0 ng/ml
Within-Run Precision		≤10%	
Between-Run Precision		≤15%	

Method Comparison:

The assay was compared with HITACHI 7600/OLYMPUS AU5400 and its matching CK-MB test kits, SIEMENS IMMULITE 1000/2000 and its matching cTnI and Myo test kits with 200

serum samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for CK-MB is 0.928, the correlation coefficient (r) for cTnl is 0.952, the correlation coefficient (r) for Myo is 0.938.

LIMITATIONS

- 1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
- Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

- Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
- EN ISO 18113-1:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
- EN ISO 18113-2:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part
 In vitro diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on CK-MB/ cTnl/Myo Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer Do not reuse		Expiration date
8			Date of manufacture
\square i	Consult instructions for use	LOT	Batch code
1	Temperature limitation	IVD	In vitro diagnostic medical device
Σ	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark	®	Do not use if package is damaged

Thank you for purchasing CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF09-S-02



Getein Biotech, Inc.

Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China

Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn







Cardiac Troponin I **Fast Test Kit**

(Immunofluorescence Assav)

User Manual

Getein1100: Cat # IF1001 Getein1600: Cat # IF2001

INTENDED USE

Cardiac Troponin I Fast Test Kit (Immunofluorescence Assav) is intended for in vitro quantitative determination of Cardiac Troponin I (cTnI) in serum, plasma or whole blood. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Troponin, a molecular complex that is bound to the thin filament (actin) of striated muscle fibers, acts with intracellular calcium to control the interaction of the thin filament with the thick filament (myosin), thus regulating muscle contraction. Troponin consists of three regulatory proteins: T. which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium: C. which binds calcium. Cardiac Troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of Troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardium.

Clinical studies have demonstrated the release of cTnI into the blood stream within hours following acute myocardial infarction (AMI) or ischemic damage. Elevated levels of cTnI are detectable in blood within 4 to 6 hours after the onset of chest pain. reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnI has become an important marker in the diagnosis and evaluation of patients suspected of having an AMI.

The current guideline of The Joint European Society of Cardiology/ American College of Cardiology Committee support the use of cTnI as a preferred marker of myocardial injury. Several major studies have shown that cTnI is also a predictor of cardiac risk in patients with unstable angina. The American College of Cardiology and the American Heart Association's current

guidelines recommend using troponin results when making treatment decisions regarding unstable angina and non-ST segment elevation MI (NSTEMI).

PRINCIPLE

The test uses an anti-human cTnI monoclonal antibody conjugated with fluorescence latex and another anti-human cTnl monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled antihuman cTnI monoclonal antibody binds with the cTnI in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human cTnI monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of cTnI in sample.

Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of cTnI in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

1.	A kit for Getein1100 contains: Getein cTnI test card in a sealed pouch with desiccant25
	Disposable pipet 25 Whole blood buffer 1 SD card 1
2.	User manual
	Sealed cartridge with 24/48 Getein cTnI test cards ······ 2
	User manual
	2×24 tests/kit, 2×48 tests/kit
	Materials required for Getein1600: Sample diluent
	Box with pipette tips
	Mixing plate
3.	Sample diluent/Whole blood buffer composition:
	Phosphate buffered saline, proteins, detergent, preservative,

stabilizer. 4. A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled anti-

human cTnI monoclonal antibody, the test line is coated with another anti-human cTnI monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits,

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer Getein 1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.

For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

Store the sample diluent/whole blood buffer at 0~30°C with a valid period of 24 months.

Store the sample diluent/whole blood buffer at 2~8°C for better results

PRECAUTIONS

- 1. For in vitro diagnostic use only.
- 2. For professional use only.
- 3. Do not use the kit beyond the expiration date.
- 4. Do not use the test card if the foil pouch or the cartridge is damaged.
- 5. Do not open pouches or the cartridge until ready to perform the test.
- 6. Do not reuse the test card.
- 7. Do not reuse the pipet.
- 8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
- 9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for serum, plasma and whole blood samples. Heparin and sodium citrate should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.

- 2. Suggest using serum or plasma for better results.
- 3. Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing
- 4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8°C or stored at -20°C for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8°C).
- 5. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freezethaw cycles.
- Do not use heat-inactivated samples.
- 7. SAMPLE VOLUME (for Getein1100): 100 ul.

TEST PROCEDURE

- 1. Collect specimens according to user manual.
- 2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

- 3. Confirm SD card lot No. in accordance with test kit lot No... Perform "SD Card Calib" calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
- 4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
- 5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
- 6. Put the test card on a clean table, horizontally placed.
- 7. Using sample transfer pipette, deliver 100 µl of sample (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 100 µl sample on the test card).
- 8. Reaction time: 10 minutes. Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically. For Getein1600:

- 9. Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
- 10. Place samples in the designed area of the sample holder. insert the holder and select the right test item. Getein1600 will do the testing and print the result automatically.

Notes:

- 1. It is required to perform "SD Card Calib" calibration when using a new batch of kits.
- 2. It is suggested to calibrate once for one batch of kits for Getein1100.
- 3. Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information. please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for Troponin I was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnl is 0.1 ng/ml. (The probability that value of a normal person below 0.1 ng/ml is 99%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range 0.1~50 ng/ml Lower Detection Limit ≤ 0.1 ng/ml Within-Run Precision ≤10% Between-Run Precision ≤15% Method Comparison:

The assay was compared with SIEMENS IMMULITE 2000 and its matching cTnI test kits with 200 serum samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for cTnI is 0.952.

LIMITATIONS

- 1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
- 2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

- 1. Mauro Pantaghini. Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
- 2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice

- Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
- 3. EN ISO 18113-1:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
- 4. EN ISO 18113-2:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS LISED

The following graphical symbols used in or found on Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

	Key to symbols used			
***	Manufacturer		Expiration date	
8	Do not reuse	W	Date of manufacture	
i	Consult instructions for use	LOT	Batch code	
1	Temperature limitation	IVD	In vitro diagnostic medical device	
\sum	Sufficient for	EC REP	Authorized representative in the European Community	
((CE mark	®	Do not use if package is damaged	

Thank you for purchasing Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF02-S-02



Getein Biotech, Inc.

Add: No.9 Bofu Road, Luhe District, Naniing, 211505, China

Tel: +86-25-68568508 Fax: +86-25-68568500 E-mail: tech@getein.com.cn overseas@getein.com.cn Website: www.bio-GP.com.cn









D-Dimer Fast Test Kit

(Immunofluorescence Assav)

User Manual

Getein1100: Cat # IF1006 Getein1600: Cat.# IF2006

INTENDED USE

D-Dimer Fast Test Kit (Immunofluorescence Assav) is intended for in vitro quantitative determination of D-Dimer in plasma or whole blood. The test is used as an aid in the assessment and evaluation of patients suspected of deep-vein thrombosis or pulmonary embolism.

SUMMARY

Deep-vein thrombosis is a common condition, with a lifetime cumulative incidence of 2 to 5 percent. Untreated deep-vein thrombosis can result in pulmonary embolism, a potentially fatal outcome. Anticoagulant therapy reduces both morbidity and mortality from venous thromboembolism, and early diagnosis is therefore important. Accurate diagnosis of deep-vein thrombosis minimizes the risk of thromboembolic complications and averts the exposure of patients without thrombosis to the risks of anticoagulant therapy.

D-Dimer is a marker of endogenous fibrinolysis and should therefore be detectable in patients with deep-vein thrombosis. In recent years, an increasing number of studies have shown the D-Dimer assay has a high negative predictive value and D-Dimer is a sensitive but nonspecific marker of deep-vein thrombosis. Negative D-Dimer can exclude deep-vein thrombosis and pulmonary embolism.

PRINCIPLE

The test uses an anti-human D-Dimer monoclonal antibody conjugated with fluorescence latex and another anti-human D-Dimer monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human D-Dimer monoclonal antibody binds with the D-Dimer in sample and forms a marked antigen-antibody

complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by another anti-human D-Dimer monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of D-Dimer in sample. Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of D-Dimer in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading.

The result can be easily transmitted to the laboratory or

Getein D-Dimer test card in a sealed pouch with desiccant

CONTENTS

L Δ kit	for	Geteir	າ1100	contains:

hospital information system.

	Disposable pipet · · · · · 25
	Sample diluent ····· 25
	SD card ····································
	User manual ····································
2.	A kit for Getein1600 contains:
	Sealed cartridge with 24/48 Getein D-Dimer test cards
	2
	User manual ······ 1
	Package specifications:
	2×24 tests/kit, 2×48 tests/kit
	Materials required for Getein1600:
	Sample diluent · · · · · 1
	Box with pipette tips · · · · · 1
	Mixing plate 1
3.	Sample diluent composition:
	Phosphate buffered saline, proteins, detergent, preservative,
	stabilizer.

4. A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled antihuman D-Dimer monoclonal antibody, the test line is coated with another anti-human D-Dimer monoclonal antibody and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.

For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

Store the sample diluent/whole blood buffer at 0~30°C with a valid period of 24 months.

Store the sample diluent/whole blood buffer at 2~8°C for better results

PRECAUTIONS

- 1. For in vitro diagnostic use only.
- 2. For professional use only.
- 3. Do not use the kit beyond the expiration date.
- 4. Do not use the test card if the foil pouch or the cartridge is damaged.
- 5. Do not open pouches or the cartridge until ready to perform the test
- 6. Do not reuse the test card.
- 7. Do not reuse the pipet.
- 8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
- 9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

- 1. This test can be used for plasma and whole blood samples. Sodium citrate can be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
- 2. Suggest using plasma for better results.
- 3. If testing will be delayed, plasma sample may be stored up to 3 days at 2~8°C or stored at -20°C for 1 month before testing (whole blood sample may be stored up to 3 days at 2~8°C).
- 4. Refrigerated or frozen sample should reach room temperature

- and be homogeneous before testing. Avoid multiple freezethaw cycles.
- 5. Do not use heat-inactivated samples.
- 6. SAMPLE VOLUME (for Getein1100): 100 µl.

TEST PROCEDURE

- 1. Collect specimens according to user manual.
- 2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

- Confirm SD card lot No. in accordance with test kit lot No.. Perform "SD Card Calib" calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
- 4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
- Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
- 6. Put the test card on a clean table, horizontally placed.
- 7. Using sample transfer pipette, deliver 100 µi of sample into one tube of sample diluent, mix gently and thoroughly. Then drop 100 µl of sample mixture (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card.
- Reaction time: 10 minutes. Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.
 For Getein1600:
- Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
- 10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

- 1. It is required to perform "SD Card Calib" calibration when using a new batch of kits.
- It is suggested to calibrate once for one batch of kits for Getein1100.
- Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for D-Dimer was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for D-Dimer is 0.5 mg/L. (The probability that value of a normal person below 0.5 mg/L is 95%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

 Measuring Range
 0.1~10.0 mg/L

 Lower Detection Limit
 ≤0.1 mg/L

 Within-Run Precision
 ≤10%

 Between-Run Precision
 ≤15%

Method Comparison:

The assay was compared with SIEMENS CA-7000 and its matching D-Dimer test kits with 200 plasma samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for D-Dimer is 0.978.

LIMITATIONS

- 1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
- 2. Samples containing interferents such as rheumatoid factor, human anti-mouse antibody and heterophile antibody may influence the results. In this case, results of this test should be used in conjunction with clinical findings and other tests. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	25 g/L	0.1 g/L

REFERENCES

- Sarig G, Klil-Drori AJ, Chap-Marshak D, Brenner B, Drugan A. Activation of coagulation in amniotic fluid during normal human pregnancy. Thromb Res. 2011 Apr 18.
- Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated

- Atrial Fibrillation Patients. J Am Coll Cardiol. 2011 Apr 11.
- Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol. 2011 Mar-Apr; 52(2):123-127.
- EN ISO 18113-1:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
- EN ISO 18113-2:2009 In vitro diagnostic medical devices -Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on D-Dimer Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

	Key to symbols used						
444	Manufacturer	Expiration date					
(2)	Do not reuse	<u>~</u>	Date of manufacture				
[]i	Consult instructions for use	LOT	Batch code				
1	Temperature limitation	IVD	<i>In vitro</i> diagnostic medical device				
Σ	Sufficient for	EC REP	Authorized representative in the European Community				
CE	CE mark	®	Do not use if package is damaged				

Thank you for purchasing D-Dimer Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF05-S-02



Getein Biotech Inc.

Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China Tel: +86-25-68568508

Fax: +86-25-68568500 E-mail: tech@getein.com.cn

overseas@getein.com.cn Website: www.bio-GP.com.cn







HIGHLY EFFICIENT & ACCURATE

Advanced fluorescence immunoassay

Multiple quality control



REAL-TIME AND RAPID TEST

One-step test

3-15 min/test

5 sec/test for multiple tests

OPERATION MODES

Inside Mode (single sample rapid test mode)



Sample Transfer



Test Card Insert



Click "Start" Icon



Result Show and Print

Quick mode (mass samples rapid test mode)



Sample Transfer



Timing the Reaction Manually



Click "Start" Icon



Result Show and Print





CONVENIENT OPERATION

RFID card calibration

Keyboard and mouse connectivity through USB port

Handwriting input available

Continuous test for 3 hours with optional lithium battery



USER-FRIENDLY INTERFACE

Android system

7-inch touch screen



- 1 7-inch Touch Screen
- **2** SD Card Recognition Zone
- **3** Test Card Slot
- 4 SD Card Slot



- **5** USB Slot
- **6** Built-in Thermal Printer





PORTABLE DESIGN

Small in size: 261 \times 241 \times 115 mm

Light in weight: 2.0 kg



LARGE MEMORY

Up to 10,000 results storage capacity

TECHNICAL PARAMETERS

Methodology

Immunofluorescence

Result

Quantitative

Sample Type

WB, Plasma, Serum, Urine, Stool, Nasal swab, Saliva, Capillary blood

Storage Capacity

10000 data

Language

English/Chinese/Spanish/Portuguese

Screen

7-inch touch screen

Power Supply

100-240 V~50 Hz/60 Hz, 60 VA

Working Environment

Temperature: 10-35°C Relative humidity ≤70% Air pressure 70.0~106.0 kpa

Dimensions

261 mm \times 241 mm \times 115 mm (D \times W \times H)

Weight

2.0 kg

TEST ITEMS

Cat.#	TEST ITEMS	DISEASES	CUT-OFF VALUE	Sample Types	MEASURING RANGE	Sample Volume	REACTION TIME	QUALIFI	CATIO
Cardia	ac Markers								
IF1001	cTnI	Myocardial infarction	0.10 ng/mL	S/P/WB	0.10-50.00 ng/mL	100 μL	10 min	NMPA	CΕ
IF1098	TnT	Myocardial infarction	14.0 pg/mL	S/P/WB	10.0-10000.0 pg/mL	100 μL	15 min	NMPA	CE
IF1089	BNP	Heart failure	100.0 pg/mL	P/WB	5.0-5000.0 pg/mL	100 μL	10 min	NMPA	CE
IF1002	NT-proBNP	Heart failure	300 pg/mL	S/P/WB	100-35000 pg/mL	100 μL	10 min	NMPA	CE
IF1005	CK-MB/cTnI/Myo	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL Myo: 70.0 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL 30.0-600.0 ng/mL	100 μL	10 min	NMPA	C€
IF1012	CK-MB/cTnI	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL	100 μL	10 min	C	€
IF1014	H-FABP	Myocardial damage	6.36 ng/mL	S/P/WB	1.00-120.00 ng/mL	100 μL	3 min	NMPA	CE
IF1016	CK-MB/cTnI/H-FABP	Myocardial damage /infarction	CK-MB: 5.00 ng/mL cTnl: 0.10 ng/mL H-FABP: 6.36 ng/mL	S/P/WB	2.50-80.00 ng/mL 0.10-50.00 ng/mL 2.00-100.00 ng/mL	100 μL	10 min	NMPA	CE
IF1018	CK-MB	Myocardial injury	5.00 ng/mL	S/P/WB	2.50-80.00 ng/mL	100 μL	10 min	C	E
Coagu	ılation Marker								
IF1006	D-Dimer	Venous thromboembolism	0.50 mg/L	P/WB	0.10-10.00 mg/L	100 μL	10 min	NMPA	C€
Inflan	nmation								
IF1003	hs-CRP+CRP	Cardiovascular inflammation /normal inflammation	3.0 mg/L 10.0 mg/L	S/P/WB/ Fingertip blood	0.5-200.0 mg/L	10 μL	3 min	NMPA	CE
IF1007	PCT	Sepsis, bacterial infection	0.10 ng/mL	S/P/WB	0.05-50.00 ng/mL	100 μL	15 min	NMPA	CE
IF1015	PCT/CRP	Sepsis, bacterial infection	PCT: 0.10 ng/mL CRP: 3.0 mg/L	S/P/WB	0.10-50.00 ng/mL 0.5-200.0 mg/L	100 μL	15 min	NMPA	CE
IF1044	SAA	Bacterial/Virus infection	10.0 mg/L	S/P/WB/ Fingertip blood	5.0-200.0 mg/L	10 μL	5 min	NMPA	CE
IF1090	SAA/CRP	Neonatal sepsis, Bacterial/virus infection	SAA: 10.0 mg/L CRP: 10.0 mg/L	S/P/WB/ Peripheral blood	5.0-200.0 mg/L 0.5-200.0 mg/L	10 μL	5 min	NMPA	CE
IF1088	IL-6	Acute inflammation	7.0 pg/mL	S/P/WB/ Peripheral blood	1.5-4000.0 pg/mL	100 μL	15 min	NMPA	CE
Renal	Function								
IF1008	CysC	Acute and chronic renal diseases	0.51-1.09 mg/L	S/P/WB	0.50-10.00 mg/L	10 μL	3 min	NMPA	CE
IF1009	mAlb	Diabetic nephropathy, hypertensive nephropathy	20.0 mg/L	Urine	10.0-200.0 mg/L	100 μL	3 min	NMPA	CE
IF1010	NGAL	Acute kidney injury	Serum: 200.0 ng/mL Urine: 100.0 ng/mL	S/Urine	50.0-5000.0 ng/mL	10 μL	10 min	NMPA	CE
IF1011	β ₂ -MG	Acute and chronic kidney diseases/tumours	0.80-3.00 mg/L	S/P/WB	0.50-20.00 mg/L	10 μL	3 min	NMPA	CE
Diabe	tes Mellitus								
IF1017	HbA1c	Diabetes mellitus	3.80%-5.80%	WB	2.00%-14.00%	10 μL	5 min	NGSP IFCC	NMP CE
Metab	oolic Marker								
IF1031	25-OH-VD	Osteomalacia, osteoporosis	30.00-50.00 ng/mL	S/P	8.00-70.00 ng/mL	40 μL	15 min	NMPA	Œ
Thyro	id Function								
IF1024	TSH	Thyroid malfunction	0.27-4.20 μlU/mL	S/P	0.10-50.00 μIU/mL	100 μL	15 min	NMPA	CE
IF1022	Т3	Hyperthyroidism, hypothyroidism	1.30-3.10 nmol/L	S/P	0.30-10.00 nmol/L	40 μL	15 min	NMPA	CE
IF1023	Т4	Hyperthyroidism, hypothyroidism	59.00-154.00 nmol/L	. S/P	5.40-320.00 nmol/L	100 μL	15 min	NMPA	CE
IF1067	fT3	Hyperthyroidism, hypothyroidism	3.10-6.80 pmol/L	S/P/WB	0.60-50.00 pmol/L	100 μL	15 min	C	€
IF1068	fT4	Hyperthyroidism, hypothyroidism	12.00-22.00 pmol/L	S/P/WB	0.30-100.00 pmol/L	100 μL	15 min	C	E

Cat.#	TEST ITEMS	DISEASES	CUT-OFF VALUE	Sample Types	MEASURING RANGE	Sample Volume	REACTION TIME	QUALIFICATION
Repro	duction/Fertility							
IF1013	HCG+β	Fertility	5.1 mIU/mL	S/P	5.0-100000.0 mIU/ml	_100 μL	10 min	NMPA C€
IF1055	LH	PCOS, infertility evaluation	Refer to User Manual	S/P	0.20-150.00 mIU/mL	100 μL	15 min	NMPA C€
IF1056	FSH	PCOS, infertility evaluation and pituitary disorders	Refer to User Manual	S/P	0.20-150.00 mIU/mL	100 μL	15 min	NMPA C€
IF1066	АМН	Fertility, PCOS, gonadal function, precocious/late puberty	' Refer to User Manual	S/P	0.10-20.00 ng/mL	200 μL	15 min	C€
IF1048	PRL	Infertility, gonadal disorders	Refer to User Manual	S/P	0.50-200.00 ng/mL	100 μL	15 min	NMPA C€
IF1071	Prog	Infertility, evaluation of ovulation	Refer to User Manual	S/P	0.10-40.00 ng/mL	100 μL	15 min	C€
IF1073	Testosterone	Female polycystic ovary syndrome male testosterone insufficiency	, Male: 1.75-7.81 ng/mL Female: 0.10-0.75 ng/mL	S/P	0.10-16.00 ng/mL	100 μL	15 min	C€
IF1074	E2	Ovarian function	Refer to User Manual	S/P	40.0-4800.0 pg/mL	100 μL	15 min	C€
Tumo	r Markers							
IF1053	tPSA	Prostate cancer	4.00 ng/mL	S/P	0.50-100.00 ng/mL	100 μL	15 min	NMPA
IF1072	fPSA	Prostate cancer	1.00 ng/mL	S/P	0.05-30.00 ng/mL	100 μL	10 min	NMPA
IF1050	AFP	Liver cancer, cancer of ovaries or testicles, etc.	7.0 ng/mL	S/P	2.0-500.0 ng/mL	100 μL	15 min	C€
IF1051	CEA	Cancer marker: colon cancer etc.	4.7 ng/mL	S/P	2.0-500.0 ng/mL	100 μL	15 min	C€
Infecti	ious Disease							
IF1057	Anti-HCV	Hepatitis C	1.00 S/CO	S/P	1.00-20.00 S/CO	100 μL	15 min	
IF1058	Anti-TP	Syphilis	1.00 S/CO	S/P	1.00-50.00 S/CO	100 μL	15 min	C€
IF1059	Anti-HIV	AIDS	1.00 S/CO	S/P	1.00-1000.00 S/CO	100 μL	15 min	
IF1064	HBsAg	Hepatitis B	1.00 IU/mL	S/P	1.00-100.00 IU/mL	100 μL	15 min	
IF1063	Anti-HBs	Hepatitis B	10.00 mIU/mL	S/P/WB	10.00-1000.00 mIU/ml	_100 μL	15 min	
IF1084	2019-nCoV IgM/IgG	COVID-19	1.00 COI	S/P/WB		100 μL	10 min	C€
IF1091	SARS-CoV-2 Antigen	COVID-19	1.00 COI Nas	sal swab/Sali	iva	100 μL	15 min	C€
EW	SARS-CoV-2 Neutralizing Antibody	COVID-19		S/P/WB/ ngertip bloo		40 μL	15 min	C€
IF1047	H. pylori	H. pylori infection	5.0 ng/mL	Stool	1.0-200.0 ng/mL (a	3 drops bout 100 μL)	10 min	C€
IF1086	Influenza A/B	Respiratory viral infection	1.00 S/CO	Nasal swab		100 μL	15 min	CE
IF1136	Dengue NS1 Ag	Dengue virus infection	1.00 S/CO	S/P/WB	0.50-50.00 S/CO	100 μL	15 min	C€
Specif	ic Protein and Rh	eumatism						
IF1075	RF	Rheumatoid arthritis	15.9 IU/mL	S/P/WB	10.0-640.0 IU/mL	10 μL	10 min	CE
IF1076	ASO	Rheumatic fever, acute glomerulonephritis, group A streptococcal infection	408.0 IU/mL	S/P/WB	60.0-1370.0 IU/mL	10 μL	10 min	C€
IF1029	Anti-CCP	Rheumatoid arthritis	25.0 U/mL	S/P/WB	10.0-400.0 U/mL	10 μL	15 min	CE
Other			,	, ,				
IF1077	Ferritin	Anemia/tumors	Male: 30.00-400.00 ng/mL Female: 13.00-150.00 ng/m	s/P	0.50-1000.00 ng/mL	10 μL	15 min	C€
IF1069	Total IgE	Allergic disorders	Refer to User Manual	S/P/WB	1.00-2000.00 IU/mL	100 นโ	15 min	C€
IF1052	PG I/PG II	Atrophic gastritis, stomach cancer	PG I<70.0 ng/mL PG I/PG II<3.0 ng/mL	S/P	PG I: 1.0-200.0 ng/ml PG II: 1.0-100.0 ng/m		15 min	

Coming Soon: FOB, Folate...



Add.: No.9 Bofu Road, Luhe District, Nanjing, 211505, China Tel.: +86-25-68568508/68568594

Fax: +86-25-68568500

E-mail: sales@getein.com.cn; overseas@getein.com.cn Web.: www.getein.com



















浙江东方基因生物制品股份有限公司 Zhejiang Orient Gene Biotech Co., LTD



CE-DOC-OG060 Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: Zhejiang Orient Gene Biotech Co., Ltd

Legal Manufacturer Address: 3787#, East Yangguang Avenue, Dipu Street,

Anji 313300, Huzhou, Zhejiang, China

Declares, that the products Product Name and Model(s)

Fecal Occult Blood Rapid Test Strip (Feces)	GEFOB-601b
Fecal Occult Blood Rapid Test Cassette (Feces)	GEFOB-602b

Classification: Other

Conformity assessment route: Annex III (EC DECLARATION OF CONFORMITY)

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: Shanghai International Holding Corp. GmbH (Europe)

EC Representative's Address: Eiffestrasse 80, 20537 Hamburg, Germany

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 28, 2017

Name of authorized signatory: Joyce Pang Position held in the company: Vice-President

Tyle Py.







Product Service

Certificate

No. Q5 092305 0001 Rev. 01

Holder of Certificate: Zhejiang Orient Gene Biotech Co., Ltd.

3787#, East Yangguang Avenue, Dipu Street Anji

313300 Huzhou, Zhejiang

PEOPLE'S REPUBLIC OF CHINA

Certification Mark:



Scope of Certificate: Design and Development, Production and Distribution

of In Vitro Diagnostic Reagent and Instrument for the Detection of Drugs of Abuse, Fertility, Infectious Diseases, Oncology, Biochemistry, Cardiac Diseases, Allergic Disease based on Rapid Test, PCR and Liquid

Biochip Method.

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 01

Report No.: SH2198802

 Valid from:
 2022-04-11

 Valid until:
 2024-03-16

Date, 2022-04-11 Christoph Dicks

Head of Certification/Notified Body



Certificate

No. Q5 092305 0001 Rev. 01

Applied Standard(s): EN ISO 13485:2016

Medical devices - Quality management systems -

Requirements for regulatory purposes

(ISO 13485:2016) DIN EN ISO 13485:2016

Facility(ies): Zhejiang Orient Gene Biotech Co., Ltd.

3787#, East Yangguang Avenue, Dipu Street Anji, 313300 Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate



浙江东方基因生物制品股份有限公司 Zhejiang Orient Gene Biotech Co.,LTD

STATEMENT

We, Zhejiang Orient Gene Biotech Co., Ltd , having a registered office at 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as non-exclusive authorized representative for Orient Gene Brand product in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement letter will be valid from Feb.21th,2023 to Feb.20th, 2024.

Zhejiang Orient Gene Biotech

General Manager

Date: 2023/2/21

电话 Tel:+86-572-5226111





SYNTESYS S.A.S. DI RINALDO R. & C.

VIA G. GALILEI, 10/3 35037 Z.I. SELVE DI TEOLO (PD) TEL. +39 049 9903866 R.A. FAX +39 049 9903867 COD.FISCALE P.IVA N.REG.IMP. PADOVA 03573950288 E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT

DICHIARAZIONE DI CONFORMITA'

Conformity declaration

CE

Il sottoscritto, Rinaldo Ruggero legale rappresentante della ditta: The undersigned, Rinaldo Ruggero legal representative of the company:

produttore/manufacturer

Via G. Galilei, 10/3 35037 Zona Industriale SELVE DI TEOLO (PADOVA) ITALY

O rappresentante il mandatario autorizzato entro la Unione Europea or representing the authorized mandatary within the European Community

Mandatario autorizzato/authorized mandatary

indirizzo/address

Dichiara sotto la propria responsabilità che il prodotto/declares under his own responsability that the product:

Denominazione/Description

K3 EDTA x 2,5 ml di sangue in pr. 12x56 mm t/verde scuro / K3 EDTA green stopper 12x56 mm vol. 2,5 ml flat bottom test tube

Lotto/Lot

Data di scadenza/Expire date

Codice/Code

318540

È conforme alle disposizioni della direttiva 98/79/CE e smi, concernente i dispositivi medici diagnostici in vitro e recepito in Italia con D.L. del 08/09/2000 n° 332 allegato 1 (requisiti essenziali) ed è fabbricato in accordo ai requisiti di cui all'Allegato III della sopra citata direttiva./ It meets the CE Directive 98/79 CE about in vitro diagnotic device specifications established by the Italian law n. 332, dated 8th September 2000. The device is made according to the specifications of the III attached of the above-mentioned directive.

1000 pezzi/ 1000 pcs.

Polipropilene + Polietilene / Polypropylene + Polyethylene

Dichiara inoltre che la documentazione tecnica di supporto alla presente dichiarazione di conformità è conservata presso gli uffici dell'azienda e sarà posta alla disposizione di chi la richiede/ declares that all technical documents attached to this conformity statment are filed in our company and can be consulted by any authorized body on demand.

Data 13.12.2017

Materiale/Material

Confezione/Pack

SYNTESYS S.a.s.

Il legale rappresentante
Rinaldo Ruggero





SYNTESYS S.A.S. DI RINALDO R. & C. VIA G. GALILEI, 10/3 35037 Z.I. SELVE DI TEOLO (PD) TEL. +39 049 9903866 R.A. FAX +39 049 9903867

COD.FISCALE P.IVA N.REG.IMP. PADOVA 03573950288 E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT

DICHIARAZIONE DI CONFORMITA Conformity declaration

CE

Il sottoscritto. Rinaldo Ruggero legale rappresentante della ditta: The undersigned. Rinaldo Ruggero legal representative of the company:

produttore/manufacturer

SYNTESYS S.a.s. di Rinaldo Ruggero & C.

indirizzo/address

Via G. Galilei, 10/3 35037 Zona Industriale SELVE DI TEOLO (PADOVA) ITALY

O rappresentante il mandatario autorizzato entro la Unione Europea or representing the authorized mandatary within the European Community

Mandatario autorizzato/authorized mandatary

indirizzo/address

Dichiara sotto la propria responsabilità che il prodotto/declares under his own responsability that the product:

Denominazione degli articoli prodotti/Description of Manufacturer Contenitori per urina, contenitori per feci, contenitori universali, Pipette Pasteur, Piastre di Petri, Anse Sterili per batteriologia, Aste a "L", Puntali Eppendorf gialli e blue, cuvette per spettrofotometro, tazzine per campionamento siero, bacchette per distacco ed estrazione del coagulo, pinzette in polistirolo monouso, provette monouso in plastica, tappi alettati per provette diam. 12 mm e 15 mm, provette con granuli ed acceleratore, provette sottovuoto per prelievo, Sistema SEDIPLAST, Microprovette, Portavetrini, Vetrini precolorati, Portaprovette, supporti per microprovette, bottiglie per raccolta urine.

Urine container, faeces container, universal container, Pasteur pipette, Petri dishes, Sterile loops, Sterile loops open "L", Eppendorf tips yellow and blue, cuvettes for spectrophotometer, samples cups, Rod to detach clot, disposable forceps, Disposable plastic tubes, winged stoppers for tubes diam. 12mm & 16mm, Test tube with granules and clot activator, vacuum test tube, SEDIPLAST system, micro test tubes, Slides Mailer, "TESTSIMPLETS" slides rack for test tubes, Bottles for urine collection.





SYNTESYS S.A.S. DI RINALDO R. & C. VIA G. GALILEI, 10/3 35037 Z.I. SELVE DI TEOLO (PD) TEL. +39 049 9903866 R.A. FAX +39 049 9903867

COD.FISCALE P.IVA N.REG.IMP. PADOVA 03573950288 E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT

Materiale/Material

Polipropilene, Polistirolo, Polietilene e Polimetilmetacrilato

Polypropylene, Polystyrene, Polyethylene and Polymetilmetacrylate

È conforme alle disposizioni della direttiva 98/79/CE concernente i dispositivi medici diagnostici in vitro e recepito in Italia con D·L· del D8/09/2000 n° 332 allegato L (requisiti essenziali) ed è fabbricato in accordo ai requisiti di cui all'Allegato III della sopra citata direttiva / It meets the CE Directive 98/79 CE about in vitro diagnotic device specifications established by the Italian law n· 332, dated 8th September 2000. The device is made according to the specifications of the III attached of the above-mentioned directive.

Dichiara inoltre che la documentazione tecnica di supporto alla presente dichiarazione di conformità è conservata presso gli uffici dell'azienda e sarà posta alla disposizione di chi la richiede/declares that all technical documents attached to this conformity statment are filed in our company and can be consulted by any authorized body on demand.

Data 07/01/2016 Issued on January 7th 2016

SYNTESYS S.a.s.
Il legale rappresentante
Rinaldo Ruggero





Cert. N.7111/3







SYNTESYS S.R.L. UNIPERSONALE

VIA G. GALILEI, 10/3 - 35037 Z.I. SELVE DI TEOLO (PD)
TEL. +39 049 9903866 R.A. FAX +39 049 9903867
C.F./P.I./N.REG.IMP. PADOVA 03573950288
REA PD-320123 - CAP.50C. 20.700.006
E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT
PEC POSTA@PEC.SYNTESYS.IT

DICHIARAZIONE DI CONFORMITA' UE

EU Declaration of conformity



Il sottoscritto, Rinaldo Ruggero legale rappresentante della ditta: The undersigned, Rinaldo Ruggero legal representative of the company:

produttore/manufacturer

SYNTESYS S.r.l. – numero SRN /SRN Number: IT-MF-000027856

indirizzo/address

Via G. Galilei, 10/3 35037 Zona Industriale SELVE DI TEOLO (PADOVA) ITALY

Dichiara sotto la propria responsabilità che i prodotti/*Declares under his own responsability that the products:* Contenitori di feci /*Faeces Container* UDI di Base /*Basic UDI:* 805414149CONTFECIXB

Codice/Reference	Denominazione/Description	UDI
313114	Contenitore feci 30 ml 27x80 mm in polipropilene con tappo a vite bianco separato /Transparent polypropylene faeces container 30 ml with separated white screw cap	08054141490468
313115	Contenitore feci 30 ml 27x80 mm in polipropilene con tappo a vite rosso separato /Transparent polypropylene faeces container 30 ml with separated red screw cap	08054141490475
313117	Contenitore feci 30 ml 27x80 mm in polipropilene graduato con tappo a vite rosso e superficie di scrittura /Transparent polypropylene faeces container 30 ml with red screw cap	08054141490499
313119	Contenitore feci 30 ml 27x80 mm in polipropilene con tappo a vite rosso ed etichetta gialla /Transparent polypropylene faeces container 30 ml with red screw cap and yellow label	08054141490208
313122	Contenitore feci 30 ml 27x80 mm in polipropilene con tappo a vite bianco inserito /Transparent polypropylene faeces container 30 ml white screw cap	08054141490482
318114	Contenitore feci 60 ml 35x70 mm in polipropilene con tappo a vite separato bianco /Transparent polypropylene faeces container 60 ml with separated white screw cap	08054141490246
318115	Contenitore feci 60 ml 35x70 mm in polipropilene graduato con tappo a vite rosso inserito /Transparent polypropylene faeces container 60 ml with red screw cap	08054141490253
318121E	Contenitore feci 60 ml 35x70 mm in polipropilene graduato con tappo a vite confezione singola ed etichetta in astuccio BIO-TAINER /Polypropylene faeces container 60 ml graduated with screw cap individually wrapped, single box, "BIO-TAINER"	08054141492394
318122	Contenitore feci 60 ml 35x70 mm in polipropilene graduato con tappo a vite rosso confezione singola con scrittura /Polypropylene faeces container 60 ml red screw cap individually wrapped	08054141490277
318315	Contenitore feci 60 ml 35x70 mm in polipropilene graduato con tappo a vite rosso inserito ed etichetta /Polypropylene faeces container 60 ml 35x70 mm graduated with inserted red screw cap labelled	08054141492714





Cert. N.7111/3







SYNTESYS S.R.L. UNIPERSONALE

VIA G. GALILEI, 10/3 - 35037 Z.I. SELVE DI TEOLO (PD)
TEL. +39 049 9903866 R.A. FAX +39 049 9903867
C.F./P.I./N.REG.IMP. PADOVA 03573950288
REA PD-320123 - CAP.SOC. 20.700,006
E-MAIL INFO@SYNTESYS.IT - WEB WWW.SYNTESYS.IT
PEC POSTA@PEC.SYNTESYS.IT

Contenitore feci 60 ml 35x70 mm tappo a vite rosso ed etichetta ir faeces container 60 ml red screw wrapped	confezione singola /Polypropylene
---	-----------------------------------

Sono conformi secondo il Regolamento (UE) 2017/746 concernente i Dispositivi Medico-Diagnostici in vitro e soddisfano tutti i requisiti specificati. I dispositivi sono stati classificati appartenenti alla Classe A secondo la Regola 5 dell'Allegato VIII / The products comply with the Regulation (EU) 2017/746 concerning In Vitro Diagnostic Medical Devices and meet all the specified requirements. The devices have been classified as belonging to Class A according to Rule 5 of Annex VIII.

Dichiara inoltre che la documentazione tecnica di supporto alla presente dichiarazione di conformità è conservata presso gli uffici dell'azienda e sarà messa a disposizione delle autorità competenti secondo quanto prescritto dall'Art. 10 punto 7 del Regolamento. / It also declares that the technical documentation supporting this declaration of conformity is kept at the company offices and will be made available to the competent authorities in accordance with the provisions of Art. 10 point 7 of the Regulations.

Data/ Date 23.11.2023

SYNTESYS S.R.L.
UNIPERSONALE
Il Legale Rappresentante
Rinaldo Ruggero









SYNTESYS S.R.L. UNIPERSONALE

VIA G. GALILEI, 10/3 - 35037 Z.I. SELVE DI TEOLO (PD)
TEL. *39 049 9903866 R.A. FAX *39 049 9903867
C.F./P.I./N.REG.IMP. PADOVA 03573950288
REA PD-320123 - CAP.50C. 20.700,006
E-MAIL INFO@SYNTESYS.IT
PEC POSTA@PEC.SYNTESYS.IT

AUTHORIZATION LETTER

We, **Syntesys S.R.L.** having a registered office at Via G. Galilei 10/3, 35037 Selve di Teolo - PD - Italy, assign **Sanmedico SRL** having a registered office at A.Corobceanu str., apt. 9, Chişinău MD-2012, Moldova, as authorized representative.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This letter is valid till 28.08.2024

Teolo, 28.08.2023

SYNTESYS S.R.L.

Via G. Galilei, 10/3 - 35037 Z.I. Selve - Teolo (PD) C.F.P.I./R.I. PD: 03573950288 - Cap. Soc. 20.700,00 € Tel. 049 9903866 - Fax 049 9903867

Rinaldo Ruggero
CEO and Legal Representative
SYNTESYS S.R.L.



Certificate

CISQ/ICIM S.P.A. has issued an IQNet recognized certificate that the organization:

SYNTESYS S.R.L.

Head Office and Operative Unit

Via G. Galilei, 10/1-2-3 - Zona Industriale - I-35037 Selve di Teolo (PD)

Operative Units

Via G. Galilei, 16/1 - Zona Industriale - I-35037 Selve di Teolo (PD)

Via San Benedetto, 48/A - Zona Industriale - I-35037 Selve di Teolo (PD) Via G. Galilei, 3 - Zona Industriale - I-35037 Selve di Teolo (PD)

has implemented and maintains a/an

Quality Management System

for the following scope:

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

which fulfils the requirements of the following standard:

ISO 9001:2015

Issued on: 2022-06-05
First issued on: 2013-06-05
Expires on: 2025-06-04

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document.

Registration Number: IT-83562

Alex Stoichitoiu

President of IQNET

Mario Romersi President of CISQ



This attestation is directly linked to the IQNET Member's original certificate and shall not be used as a stand-alone document.

IQNET Members*:

AENOR Spain AFNOR Certification France APCER Portugal CCC Cyprus CISQ Italy CQC China CQM China CQS Czech Republic Cro Cert Croatia DQS Holding GmbH Germany EAGLE Certification Group USA FCAV Brazil FONDONORMA Venezuela ICONTEC Colombia ICS Bosnia and Herzegovina Inspecta Sertifiointi Oy Finland INTECO Costa Rica IRAM Argentina JQA Japan KFQ Korea LSQA Uruguay MIRTEC Greece MSZT Hungary Nemko AS Norway NSAI Ireland NYCE-SIGE México PCBC Poland Quality Austria Austria SII Israel SIQ Slovenia SIRIM QAS International Malaysia SQS Switzerland SRAC Romania TSE Turkey YUQS Serbia





CERTIFICATO N. CERTIFICATE No.

6574/3

SI CERTIFICA CHE IL SISTEMA DI GESTIONE PER LA QUALITÀ DI WE HEREBY CERTIFY THAT THE QUALITY MANAGEMENT SYSTEM OPERATED BY

SYNTESYS S.R.L.

Sede e Unità Operativa

Via G. Galilei, 10/1-2-3 - Zona Industriale - 35037 Selve di Teolo (PD) - Italia Commercializzazione di prodotti per analisi di laboratorio. Produzione di prodotti per analisi di laboratorio e articoli sanitari. Progettazione e gestione della produzione di tamponi sterili per la raccolta e la conservazione di campioni biologici, anche in ambito chirurgico, con o senza terreno di trasporto.

Unità Operative

Via G. Galilei, 16/1 - Zona Industriale - 35037 Selve di Teolo (PD) - Italia * Via San Benedetto, 48/A - Zona Industriale - 35037 Selve di Teolo (PD) - Italia * Via G. Galilei, 3 - Zona Industriale - 35037 Selve di Teolo (PD) - Italia * * Magazzino.

È CONFORME ALLA NORMA / IS IN COMPLIANCE WITH THE STANDARD

UNI EN ISO 9001:2015

Sistema di Gestione per la Qualità / Quality Management System

PER LE SEGUENTI ATTIVITÀ / FOR THE FOLLOWING ACTIVITIES

EA: 29 - 14

Commercializzazione di prodotti per analisi di laboratorio. Produzione di prodotti per analisi di laboratorio e articoli sanitari. Progettazione e gestione della produzione di tamponi sterili per la raccolta e la conservazione di campioni biologici, anche in ambito chirurgico, con o senza terreno di trasporto.

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

> Riferirsi alla documentazione del Sistema di Gestione per la Qualità aziendale per l'applicabilità dei requisiti della norma di riferimento Refer to the documentation of the Quality Management System for details of application to reference standard requirements.

Il presente certificato è soggetto al rispetto del documento ICIM "Regolamento per la certificazione dei sistemi di gestione" e al relativo Schema specifico.

The use and the validity of this certificate shall satisfy the requirements of the ICIM document "Rules for the certification of company management systems" and specific Scheme.

Per informazioni puntuali e aggiornate circa eventuali variazioni intervenute nello stato della certificazione di cui al presente certificato, si prega di contattare il n° telefonico +39 02 725341 o indirizzo e-mail info@icim.it. For timely and updated information about any changes in the certification status referred to in this certificate, please contact the number +39 02 725341 or email address info@icim.it.

DATA EMISSIONE FIRST ISSUE 05/06/2013

EMISSIONE CORRENTE CURRENT ISSUE 05/06/2022

DATA DI SCADENZA **EXPIRING DATE** 04/06/2025

Mincenzo Delacqนุล Rappresentante Direzione / Management Representative

ICIM S.p.A.

Piazza Don Enrico Mapelli, 75 – 20099 Sesto San Giovanni (MI) www.icim.it





www.cisq.com





Certificate

CISQ/ICIM S.P.A. has issued an IQNet recognized certificate that the organization:

SYNTESYS S.R.L.

Head Office and Operative Unit

Via G. Galilei, 10/1-2-3 - Zona Industriale - I-35037 Selve di Teolo (PD)

Operative Units

Via G. Galilei, 16/1 - Zona Industriale - I-35037 Selve di Teolo (PD)

Via San Benedetto, 48/A - Zona Industriale - I-35037 Selve di Teolo (PD) Via G. Galilei, 3 - Zona Industriale - I-35037 Selve di Teolo (PD)

has implemented and maintains a/an

Quality Management System

for the following scope:

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

which fulfils the requirements of the following standard:

ISO 13485:2016

Issued on: 2022-06-05
First issued on: 2014-06-21
Expires on: 2025-06-04

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document.

Registration Number: IT-93779

Alex Stoichitoiu

President of IQNET

Mario Romersi
President of CISQ



This attestation is directly linked to the IQNET Member's original certificate and shall not be used as a stand-alone document.

IQNET Members*:

AENOR Spain AFNOR Certification France APCER Portugal CCC Cyprus CISQ Italy CQC China CQM China CQS Czech Republic Cro Cert Croatia DQS Holding GmbH Germany EAGLE Certification Group USA FCAV Brazil FONDONORMA Venezuela ICONTEC Colombia ICS Bosnia and Herzegovina Inspecta Sertificinti Oy Finland INTECO Costa Rica IRAM Argentina JQA Japan KFQ Korea LSQA Uruguay MIRTEC Greece MSZT Hungary Nemko AS Norway NSAI Ireland NYCE-SIGE México PCBC Poland Quality Austria Austria SII Israel SIQ Slovenia SIRIM QAS International Malaysia SQS Switzerland SRAC Romania TSE Turkey YUQS Serbia





CERTIFICATO n. CERTIFICATE No.

7111/3

SI CERTIFICA CHE IL SISTEMA DI GESTIONE PER LA QUALITÀ DI WE HEREBY CERTIFY THAT THE QUALITY MANAGEMENT SYSTEM OPERATED BY

SYNTESYS S.R.L.

Sede e Unità Operativa

Via G. Galilei, 10/1-2-3 - Zona Industriale - 35037 Selve di Teolo (PD) – Italia Commercializzazione di prodotti per analisi di laboratorio. Produzione di prodotti per analisi di laboratorio e articoli sanitari. Progettazione e gestione della produzione di tamponi sterili per la raccolta e la conservazione di campioni biologici, anche in ambito chirurgico, con o senza terreno di trasporto.

Unità Operative

Via G. Galilei, 16/1 - Zona Industriale - 35037 Selve di Teolo (PD) – Italia * Via San Benedetto, 48/A - Zona Industriale - 35037 Selve di Teolo (PD) – Italia * Via G. Galilei, 3 - Zona Industriale - 35037 Selve di Teolo (PD) – Italia * * Magazzino.

È CONFORME ALLA NORMA / IS IN COMPLIANCE WITH THE STANDARD

UNI CEI EN ISO 13485:2016

Sistema di Gestione per la Qualità / Quality Management System

PER LE SEGUENTI ATTIVITÀ / FOR THE FOLLOWING ACTIVITIES

Commercializzazione di prodotti per analisi di laboratorio. Produzione di prodotti per analisi di laboratorio e articoli sanitari. Progettazione e gestione della produzione di tamponi sterili per la raccolta e la conservazione di campioni biologici, anche in ambito chirurgico, con o senza terreno di trasporto.

Trading of products for laboratory analysis. Manufacturing of products for laboratory analysis and sanitary products. Design and production management of sterile swabs for the collection and the preservation of biological samples, also for surgical application, with or without transport medium.

Riferirsi alla documentazione del Sistema di Gestione per la Qualità aziendale per l'applicabilità dei requisiti della norma di riferimento Refer to the documentation of the Quality Management System for details of application to reference standard requirements.

Il presente certificato è soggetto al rispetto del documento ICIM "Regolamento per la certificazione dei sistemi di gestione" e al relativo Schema specifico.

The use and the validity of this certificate shall satisfy the requirements of the ICIM document "Rules for the certification of company management systems" and Specific Scheme.

Per informazioni puntuali e aggiornate circa eventuali variazioni intervenute nello stato della certificazione di cui al presente certificato, si prega di contattare il n° telefonico +39 02 725341 o indirizzo e-mail info@icim.it.

For timely and updated information about any changes in the certification status referred to in this certificate, please contact the number +39 02 725341 or email address info@icim.it.

DATA EMISSIONE FIRST ISSUE 21/06/2014

EMISSIONE CORRENTE CURRENT ISSUE 05/06/2022 DATA DI SCADENZA EXPIRING DATE 04/06/2025

Vincenzo Delaggua
Rappresentante Direzione / Management Representative

ICIM S.p.A.

Piazza Don Enrico Mapelli, 75 – 20099 Sesto San Giovanni (MI) www.icim.it



